June Transparency Reviews Create a Timely Test for Modello 231 Controls

For Italian life sciences companies, the June transparency disclosure period is a timely moment to review whether internal controls under Legislative Decree 231/2001 are aligned with financial interactions involving healthcare professionals and healthcare organisations.

This is not a new legal deadline under Legislative Decree 231/2001. Rather, it is a practical compliance checkpoint. June is when many European pharmaceutical companies finalise or publish transparency disclosures relating to Transfers of Value, making it a natural point to test whether grants, sponsorships, consultancy fees, hospitality, and other HCP/HCO interactions have been properly reviewed and documented. (EFPIA)

In Italy, Legislative Decree 231/2001 introduced corporate liability for certain offences committed by employees, managers, or collaborators, including corruption-related risks. Life sciences companies commonly address this through organisational, management, and control models designed to prevent misconduct. (ICLG)

The link with transparency reporting is operational. If ToV data reveals unclear approvals, weak documentation, inconsistent classifications, or unexplained payments, those same issues may also indicate weaknesses in anti-bribery controls, delegation processes, or monitoring under the company’s Modello 231.

For compliance teams, the June disclosure cycle should therefore be used as more than a reporting exercise. It should become a control review: do the payments disclosed externally match the company’s internal approvals, contracts, evidence, and risk controls?